ArchiMed hired five people as it expands its presence in New York, including partner Justin Bateman, who joined from BC Partners. Other hires were Monica Holec, principal of investor relations; Anthony Farias, associate director; and strategic partners Carlos Alonso and Nick Pachuda. Bateman worked at BC Partners over two decades, moving into the managing partner role. He co-founded the firm’s New York office in 2008.
Leading global private equity healthcare specialist ArchiMed, is expanding its New York City office with five appointments, adding to three transfers from the Lyon office.
The new hires at ArchiMed’s New York office are Partner Justin Bateman; Principal of Investor Relations Monica Holec; Associate Director Anthony Farias; and Strategic Partners Carlos Alonso and Nick Pachuda. They are joining company Chairman Denis Ribon, Partner Antoine Faguer and Senior Analyst Isaac Haq.
Justin Bateman joins from BC Partners, where he rose to Managing Partner during a 20-year career and co-founded the group’s New York office in 2008. He was a member of BC’s investment committee and led 14 transactions across North America and Europe representing approximately $3 billion of invested capital with an emphasis on the healthcare space.
Monica Holec was a Senior Managing Director and Head of Investor Relations at Levine Leichtman Capital Partners (“LLCP”). During her decade-long career at LLCP, Monica was responsible for internalizing the investor relations and fundraising function and managing the firm’s LP relationships globally.
Anthony Farias previously worked as a private equity professional at MacAndrews & Forbes. He began his career at JP Morgan in the healthcare group. He holds an MBA from the Wharton School of the University of Pennsylvania.
Carlos Alonso has over 30 years of international operating experience in the healthcare industry, most recently as President, International at Hill-Rom Holdings. Carlos is the Chairman of the Board of Direct Healthcare Group (DHG), a portfolio company of ArchiMed headquartered in the United Kingdom.
Nick Pachuda is a former Orthopedics Surgeon who spent the past 17 years developing new product strategies and cross-selling opportunities for a range of healthcare businesses. He most recently served as the leader and Worldwide Vice-President of Orthopedic Innovation for Johnson and Johnson Medical Devices Group.
Denis Ribon, Chairman, commented, “We are thrilled with the addition of Monica, Justin, Anthony, Carlos and Nick to the ArchiMed team. They bring a wealth of experience to the firm, expanding on the 45 professionals in Europe who also have significant US operating and investment experience. The US is a key market for us as our European investments derive most of their revenues from this side of the Atlantic. Our proven success in this market was reinforced in 2020 by four completed investments across the healthcare IT, medical devices and CRO sectors. Our recent investment in Ohio-based NAMSA, a global leading medical device CRO business and add-on of New York based Syntactx are great examples of our demonstrated expertise of scaling market leading healthcare businesses globally.”
Justin Bateman, Partner, commented “I am excited to be joining the team at ArchiMed. They have established a world class combination of healthcare, operational and investment professionals alongside its MedTalentsTM network that are highly appealing. ArchiMed’s target sectors have significant international reach, and the Firm’s operational capability in both Europe and the US are valuable drivers for maximizing growth and delivering outsized investment returns for our limited partners.”
About ArchiMed – www.archimed-group.eu
ArchiMed is a leading private equity firm focused exclusively on the healthcare industry. ArchiMed serves as a strategic and financial partner to European and North American small and middle-market businesses in targeted segments of healthcare, including pharmaceuticals, medical devices & technology, healthcare IT and consumer health. ArchiMed’s strategy is based upon healthcare specialization, integrated private equity, medical and operating expertise, and its unique trans-Atlantic platform that supports growth through internationalization.
Over the last 20 years, ArchiMed’s leadership team has directly managed and invested in over 40 small to large-size healthcare companies globally, representing over €5 billion of invested capital. ArchiMed currently manages nearly €2 billion in assets across four funds, small-cap focused MED I and MED II, gene & cell therapy focused PolyMED and mid-cap-focused MED Platform I. The latter is Europe’s largest healthcare fund at €1 billion. ArchiMed’s MED I 2014 vintage fund is the top performing buyout fund on a global level for its vintage, returning in excess of six times invested capital on a gross basis. ArchiMed is an impact investor and a signatory of the Principles for Responsible Investment, pledged to uphold the United Nations’ Sustainable Development Goals.